Incidence of extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates that test susceptible to Cephalosporins and aztreonam by the revised CLSI breakpoints

Carla S. McWilliams, Susan Condon, Rebecca M. Schwartz, Christine C. Ginocchio

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

The incidence of aztreonam and cephalosporin susceptibility, determined using the revised CLSI breakpoints, for extendedspectrum-β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae isolates was evaluated. Our analysis showed that results for aztreonam and/or ≥ 1 cephalosporin were reported as susceptible or intermediate for 89.2% of ESBLproducing E coli isolates (569/638 isolates) and 67.7% of ESBL-producing K. pneumoniae isolates (155/229 isolates).

Original languageEnglish
Pages (from-to)2653-2655
Number of pages3
JournalJournal of Clinical Microbiology
Volume52
Issue number7
DOIs
StatePublished - Jul 2014
Externally publishedYes

Fingerprint

Dive into the research topics of 'Incidence of extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates that test susceptible to Cephalosporins and aztreonam by the revised CLSI breakpoints'. Together they form a unique fingerprint.

Cite this